Finance

Lists
Q3 2026 earnings • released • EPS beat +6,37% • Revenue beat +2,93%
See results
GH:NASDAQ
Guardant Health Inc
150,87 USD
-1,67%
(-2,56) 1D
150,00 USD
-0,58% (-0,87)
After hours
Closed: 6-ноя., 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GH...
Open
141,83 USD
High
152,60 USD
Low
136,42 USD
Mkt. cap
20,25 млд
Avg. vol.
1,86 млн
Volume
5,51 млн
52-wk high
191,05 USD
52-wk low
74,55 USD
EPS
-3,50 USD
Beta
1,67
Shares outstanding
134,20 млн
No. of employees
2 миң
Open
141,83 USD
High
152,60 USD
Low
136,42 USD
Mkt. cap
20,25 млд
Avg. vol.
1,86 млн
Volume
5,51 млн
52-wk high
191,05 USD
52-wk low
74,55 USD
EPS
-3,50 USD
Beta
1,67
Shares outstanding
134,20 млн
No. of employees
2 миң
News stories
From web sources and news partners
Yahoo Finance
Yahoo Finance
·
1 күн мурун
Guardant Health, Inc. (GH) Stock Forecasts
Investor's Business Daily
Investor's Business Daily
·
2 күн мурун
Blood-Testing Gore Continues As Natera, Guardant Report
Profile
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers. Wikipedia
About Guardant Health Inc
CEOHelmy Eltoukhy | AmirAli Talasaz
Employees2,5 миң
Founded2012
HeadquartersПало Альто, Калифорния, Америка Кошмо Штаттары
SectorHealth Care
IndustryHealth care provider
Analyst ratings
Based on 19 analysts giving stock ratings to GH in the past 3 months
Strong buy
Buy
19
Hold
0
Sell
0
12-month forecast
Based on 19 Wall Street analysts offering 12 month price targets for GH in the last 3 months.
Highest
Current 150,87 USD
225,00 USD (+49,14%)
Average
204,19 USD (+35,34%)
Lowest
180,00 USD (+19,31%)
Analyst
Recommendation
Action
Price target
Projected
Date
Lu Li
Bank of America Securities
Buy
Maintained
-
-
11/06/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
180,00 USD
+19,3%
11/06/2026
Evie Koslosky
Goldman Sachs
Buy
Maintained
210,00 USD
+39,2%
11/06/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Reiterated
205,00 USD
+35,9%
11/06/2026
David Westenberg
Piper Sandler
Buy
Maintained
193,00 USD
+27,9%
11/06/2026
Dan Leonard
RBC Capital
Buy
Maintained
200,00 USD
+32,6%
11/06/2026
Daniel Brennan
TD Cowen
Buy
Maintained
220,00 USD
+45,8%
11/06/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
196,00 USD
+29,9%
11/06/2026
Luke Sergott
Barclays
Buy
Maintained
220,00 USD
+45,8%
11/06/2026
Mark Massaro
BTIG
Buy
Maintained
210,00 USD
+39,2%
10/27/2026
Max Masucci
Roth MKM
Buy
Initiated
200,00 USD
+32,6%
10/22/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Maintained
200,00 USD
+32,6%
10/20/2026
Eve Burstein
Bernstein
Buy
Reiterated
210,00 USD
+39,2%
10/19/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
195,00 USD
+29,3%
10/14/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
200,00 USD
+32,6%
10/09/2026
Subbu Nambi
Guggenheim
Buy
Maintained
200,00 USD
+32,6%
10/01/2026
William Bonello
Craig-Hallum
Buy
Maintained
-
-
09/15/2026
Unknown Analyst
UBS
Buy
Maintained
225,00 USD
+49,1%
09/09/2026
Doug Schenkel
UBS
Buy
Maintained
225,00 USD
+49,1%
09/09/2026
Jamie Clark
Rothschild & Co Redburn
Buy
Initiated
203,00 USD
+34,6%
09/08/2026
Matt Larew
William Blair
Buy
Maintained
-
-
09/08/2026
Bradley Bowers
Mizuho Securities
Buy
Maintained
200,00 USD
+32,6%
08/04/2026
Mason Carrico
Stephens
Buy
Maintained
195,00 USD
+29,3%
08/04/2026
Brandon Couillard
Wells Fargo
Buy
Maintained
125,00 USD
-17,1%
07/29/2026
Patrick B Donnelly
Citi
Buy
Maintained
215,00 USD
+42,5%
07/08/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
200,00 USD
+32,6%
07/06/2026
Puneet Souda
Leerink Partners
Buy
Reiterated
-
-
06/02/2026
Paige Chamberlain‏
Wolfe Research
Buy
Reiterated
150,00 USD
-0,6%
06/01/2026
Unknown Analyst
Wolfe Research
Buy
Reiterated
150,00 USD
-0,6%
06/01/2026
Andrew Brackmann
William Blair
Buy
Maintained
-
-
05/27/2026
Andrew Cooper
Raymond James
Buy
Reiterated
129,00 USD
-14,5%
02/23/2026
Last report
2026-ж., 5-ноя.
Fiscal period
Q3 2026
-0,29 USD / -0,31 USD
+6,37%beat
Revenue / Est. (USD)
360,98 млн / 350,71 млн
+2,93%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
281,27 млн
301,66 млн
334,98 млн
360,98 млн
Cost of goods sold
99,49 млн
104,92 млн
115,95 млн
-
Cost of revenue
99,49 млн
104,92 млн
115,95 млн
-
Research and development expenses
98,26 млн
91,04 млн
96,53 млн
100,84 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
204,20 млн
227,06 млн
250,61 млн
-
Operating expense
302,46 млн
318,10 млн
347,15 млн
-
Total operating expenses
401,96 млн
423,02 млн
463,10 млн
-
Operating income
-120,69 млн
-121,35 млн
-128,12 млн
-133,76 млн
Other non operating income
-4,69 млн
1,55 млн
308,00 миң
342,00 миң
EBT including unusual items
-130,22 млн
-111,70 млн
-119,96 млн
-
EBT excluding unusual items
-116,52 млн
-111,70 млн
-118,96 млн
-
Income tax expense
-1,73 млн
372,00 миң
185,00 миң
-
Effective tax rate
1,33%
-0,33%
-0,15%
-0,28%
Other operating expenses
-
-
-
-
Net income
-128,49 млн
-112,08 млн
-120,14 млн
-
Net profit margin
-45,68%
-37,15%
-35,87%
-34,45%
Earnings per share
-0,50
-0,45
-0,42
-0,29
Interest and investment income
10,03 млн
11,15 млн
10,20 млн
-
Interest expense
-1,18 млн
-3,05 млн
-1,35 млн
-
Net interest expenses
8,85 млн
8,10 млн
8,85 млн
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-110,64 млн
-111,91 млн
-118,56 млн
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору